Supplements

Continuous glucose monitoring identifies asymptomatic hypoglycemia and improves glycemic control in hepatic glycogen storage diseases

CGM consistently detected asymptomatic hypoglycemia in GSD patients, with adult cohorts spending up to 12% of time below 70 mg/dL despite normal spot checks. CGM-guided dietary titration improved Time in Range from 72% to 86% in gene therapy trials and reduced serum triglycerides and liver size.

Last updated: Jul 7, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes.

observational

Mohsenipour R, Abbasi F, Ghaderian MS, Dehkordi AK, Abdolahpour S, Akbari K · Endocrinology, diabetes & metabolism (2026)

Participants: N/A
Duration: N/A
Intervention: CGM-guided dietary titration
Outcome: Time in Range (TIR), serum triglycerides, liver size
Effect Size: N/A
Population: Patients with hepatic Glycogen Storage Diseases (GSD), predominantly GSD Ia, Ib and III

Result:

PubMed: 42394382DOI: 10.1002/edm2.70274

Mechanism Graph

CGM provides continuous interstitial glucose readings
↓
Detects rapid hypoglycemic excursions missed by intermittent monitoring
↓
Guides dietary adjustments to stabilize glucose levels
↓
Result: Improved Time in Range and reduced metabolic complications

Limitations

  • ⚠Sensor performance shows positive bias in the hypoglycemic range, potentially masking severe neuroglycopenia
  • ⚠CGM introduces 'alarm fatigue' from false-positive alerts, increasing patient burden

Frequently Asked Questions

What is the main benefit of CGM in GSD patients?▼

CGM provides superior sensitivity for detecting occult hypoglycemia that is missed by spot checks, allowing proactive stabilization of glucose levels.

Does CGM improve clinical outcomes in GSD?▼

Yes, CGM-guided dietary titration improved Time in Range (e.g., from 72% to 86% in gene therapy trials) and reduced serum triglycerides and liver size.

What are the downsides of using CGM in GSD?▼

CGM sensors have a positive bias in the hypoglycemic range, which can mask severe low glucose events, and patients may experience alarm fatigue from false-positive alerts.

Which GSD subtypes were studied?▼

The review predominantly included GSD subtypes Ia, Ib, and III.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Mohsenipour R, Abbasi F, Ghaderian MS, Dehkordi AK, Abdolahpour S, Akbari K. "Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes.." Endocrinology, diabetes & metabolism, 2026. PMID: 42394382 DOI: 10.1002/edm2.70274
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.